» Articles » PMID: 21915733

Pharmacokinetic Differences Between the Epimers of Cefotetan Disodium After Single Intravenous Injection in Healthy Chinese Volunteers

Overview
Date 2011 Sep 15
PMID 21915733
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

The pharmacokinetic behaviors of the epimers of cefotetan disodium (R-CTT, S-CTT) after a single intravenous injection dose in healthy Chinese volunteers were explored in this study. In an open-label, randomized, three-way, cross-over study, 12 volunteers (6 females and 6 males) received a cross-over fashion doses of 0.5, 1.0, and 2.0 g of cefotetan disodium, separated by washout periods of 7 days. The plasma concentrations of both epimers were measured by validated high-performance liquid chromatography assays. Pharmacokinetic parameters of R-CTT, S-CTT, and total-CTT (R + S mixture) were calculated using a noncompartmental analysis. Generally, the R and S epimers showed different pharmacokinetic behaviors. Following 0.5, 1.0, and 2.0 g doses of cefotetan disodium, values of the total area under the plasma concentration-time curve (AUC(0-∞)) were 124.23 ± 19.54, 231.34 ± 39.34, and 459.09 ± 80.65 for R-CTT; 100.95 ± 14.19, 193.80 ± 30.42, and 372.66 ± 67.32 for S-CTT, respectively. Total body clearance values were 4.13, 4.43, and 4.46 L/h for R-CTT and 5.05, 5.28, and 5.50 L/h for S-CTT, respectively. Mean plasma elimination half-life (t (1/2)) values of R-CTT were 4.16, 4.13, and 4.01 h for 0.5, 1.0, and 2.0 g doses, respectively, and those of S-CTT were 3.15, 3.25, and 3.21 h. There were significant differences in t (1/2) between the two epimers (P < 0.05). The t (1/2) of R-CTT was 28% longer than that of S-CTT, which indicated that the elimination of the S-CTT was greater than that of the R-CTT. All treatments were well tolerated.

Citing Articles

Population Pharmacokinetics and Dosing Regimen Optimization of Latamoxef in Chinese Children.

Wang Y, Sun D, Mei Y, Wu S, Li X, Li S Pharmaceutics. 2022; 14(5).

PMID: 35631619 PMC: 9146031. DOI: 10.3390/pharmaceutics14051033.


Pharmacokinetics and Tolerability of Single and Multiple Intravenous Doses of Cefotetan Disodium in Healthy Chinese Volunteers.

Liu J, Zhai Y, Wu L, Wu G, Zheng Y, Hu X Drug Des Devel Ther. 2020; 14:613-620.

PMID: 32103903 PMC: 7025654. DOI: 10.2147/DDDT.S234619.

References
1.
Ohkawa M, Hirano S, Tokunaga S, Motoi I, Shoda R, Ikeda A . Pharmacokinetics of cefotetan in normal subjects and patients with impaired renal function. Antimicrob Agents Chemother. 1983; 23(1):31-5. PMC: 184611. DOI: 10.1128/AAC.23.1.31. View

2.
Kees F, Grobecker H, Naber K . High-performance liquid chromatographic analysis of cefotetan epimers in human plasma and urine. J Chromatogr. 1984; 305(2):363-71. DOI: 10.1016/s0378-4347(00)83350-2. View

3.
Martin C, Thomachot L, Albanese J . Clinical pharmacokinetics of cefotetan. Clin Pharmacokinet. 1994; 26(4):248-58. DOI: 10.2165/00003088-199426040-00002. View

4.
de Lalla F . Antimicrobial prophylaxis in colorectal surgery: focus on ertapenem. Ther Clin Risk Manag. 2009; 5:829-39. PMC: 2773751. DOI: 10.2147/tcrm.s3101. View

5.
Welage L, Borin M, Wilton J, Hejmanowski L, WELS P, Schentag J . Comparative evaluation of the pharmacokinetics of N-methylthiotetrazole following administration of cefoperazone, cefotetan, and cefmetazole. Antimicrob Agents Chemother. 1990; 34(12):2369-74. PMC: 172063. DOI: 10.1128/AAC.34.12.2369. View